Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas

Publisher Website
Google Scholar
Abstract
We have evaluated the effect of adjuvant chemotherapy on time to recurrence and survival in two prospective trials of women with stage I uterine sarcomas. The first trial compared surgery only to surgery plus Adriamycin. The 5‐year estimated survival rate was 36% for surgery alone and 63% for surgery plus Adriamycin. The 5‐year recurrence free rate for surgery alone was 46% as compared to 75% for surgery plus Adriamycin. The second trial, without a concurrent control group, included patients with stage I uterine sarcoma and adjuvant cyclaphosphamide, vincristine, Adriamycin, and dacarbazine (CYVADIC) chemotherapy. The 5‐year survival rate was 89% and the recurrence‐free rate was 80%. In all of these trials, as well as in the report of Van Nagell et al (Cancer 57:1451–1454, 1986) of adjuvant vincristine, actinomycin‐D, and cyclophosphamide (VAC) chemotherapy, there are too few patients to make any formal statistical comparison of the groups, although the surgery plus CYVADIC group appears to be the most promising.